Phase II study of coumarin and cimetidine in patients with metastatic renal cell carcinoma.

• DOI: 10.1200/jco.1990.8.2.325
• Publication Date: 2017-02-23T18:39:45Z
• Authors: F H Dexeus; C J Logothetis; A Sella; K Fitz; R Amato; J M Reuben; N Dozier
• Keywords: Cimetidine

Fifty patients with locally advanced or metastatic renal cell carcinoma were treated coumarin (1,2-benzopyrone) at 100 mg orally daily starting on day 1 and cimetidine 300 four times a 15. When disease progressed, was escalated to day. Three (6%; 95% confidence interval [Cl], 2% 17%) achieved partial response, one of those after dose escalation. In addition, patient had minor then progressing disease, again response All responders nonassessable primary tumors (three prior nephrectomy angioinfarction). The only major toxicity (37 moderate elevations in serum creatinine level). Immunologic studies (hypersensitivity skin testing, lymphocyte blastogenesis number lymphocytes, T helper suppressor subsets, helper: ratio), performed before therapy, showed relative lymphopenia decreased hypersensitivity skin-testing results baseline, general decline over time the cells subsets. There no enhancement any immunologic parameters tested. rate 6%, lower than previously reported; immunodeficiency noted worsened unaffected by therapy.